The new WHO Classification
of Tumors affecting the Central Nervous System
by Stephen B. Tatter, M.D., Ph.D.
In 1993 the WHO
ratified a new comprehensive classification of neoplasms affecting
the central nervous system. The classification of brain tumors is
based on the premise that each type of tumor results from the abnormal
growth of a specific cell type. To the extent that the behavior
of a tumor correlates with basic cell type, tumor classification
dictates the choice of therapy and predicts prognosis. The new WHO
system is particularly useful in this regard with only a few notable
exceptions (for example all or almost all gemistocytic astrocytomas
are actually anaplastic and hence grade III or even IV rather than
grade II as designated by the WHO system). The WHO classification
also provides a parallel grading system for each type of tumor.
In this grading sytem most named tumors are of a single defined
grade. The new WHO classification provides the standard for communication
between different centers in the United States and around the world.
An outline of this classification is provided below.
Neuroepithelial
Tumors of the CNS
- Astrocytic tumors
[glial tumors--categories I-V, below--may also be subclassified
as invasive or non-invasive, although this is not formally part
of the WHO system, the non-invasive tumor types are indicated
below. Categories in italics are also not recognized by the new
WHO classification system, but are in common use.]
- Astrocytoma
(WHO grade II)
- variants:
protoplasmic, gemistocytic, fibrillary, mixed
- Anaplastic
(malignant) astrocytoma (WHO grade III)
- hemispheric
- diencephalic
- optic
- brain
stem
- cerebellar
- Glioblastoma
multiforme (WHO grade IV)
- variants:
giant cell glioblastoma, gliosarcoma
- Pilocytic
astrocytoma [non-invasive, WHO grade I]
- hemispheric
- diencephalic
- optic
- brain
stem
- cerebellar
- Subependymal
giant cell astrocytoma [non-invasive, WHO grade I]
- Pleomorphic
xanthoastrocytoma [non-invasive, WHO grade I]
- Oligodendroglial
tumors
- Oligodendroglioma
(WHO grade II)
- Anaplastic
(malignant) oligodendroglioma (WHO grade III)
- Ependymal cell
tumors
- Ependymoma
(WHO grade II)
- variants:
cellular, papillary, epithelial, clear cell, mixed
- Anaplastic
ependymoma (WHO grade III)
- Myxopapillary
ependymoma
- Subependymoma
(WHO grade I)
- Mixed gliomas
- Mixed oligoastrocytoma
(WHO grade II)
- Anaplastic
(malignant) oligoastrocytoma (WHO grade III)
- Others (e.g.
ependymo-astrocytomas)
- Neuroepithelial
tumors of uncertain origin
- Polar spongioblastoma
(WHO grade IV)
- Astroblastoma
(WHO grade IV)
- Gliomatosis
cerebri (WHO grade IV)
- Tumors of the
choroid plexus
- Choroid
plexus papilloma
- Choroid
plexus carcinoma (anaplastic choroid plexus papilloma)
- Neuronal and
mixed neuronal-glial tumors
- Gangliocytoma
- Dysplastic
gangliocytoma of cerebellum (Lhermitte-Duclos)
- Ganglioglioma
- Anaplastic
(malignant) ganglioglioma
- Desmoplastic
infantile ganglioglioma
- desmoplastic
infantile astrocytoma
- Central
neurocytoma
- Dysembryoplastic
neuroepithelial tumor
- Olfactory
neuroblastoma (esthesioneuroblastoma)
- variant:
olfactory neuroepithelioma
- Pineal Parenchyma
Tumors
- Pineocytoma
- Pineoblastoma
- Mixed pineocytoma/pineoblastoma
- Tumors with
neuroblastic or glioblastic elements (embryonal tumors)
- Medulloepithelioma
- Primitive
neuroectodermal tumors with multipotent differentiation
- medulloblastoma
- variants:
medullomyoblastoma, melanocytic medulloblastoma, desmoplastic
medulloblastoma
- cerebral
primitive neuroectodermal tumor
- Neuroblastoma
- variant:
ganglioneuroblastoma
- Retinoblastoma
- Ependymoblastoma
Other
CNS Neoplasms
- Tumors of the
Sellar Region
- Pituitary
adenoma
- Pituitary
carcinoma
- Craniopharyngioma
- Hematopoietic
tumors
- Primary
malignant lymphomas
- Plasmacytoma
- Granulocytic
sarcoma
- Others
- Germ Cell Tumors
- Germinoma
- Embryonal
carcinoma
- Yolk sac
tumor (endodermal sinus tumor)
- Choriocarcinoma
- Teratoma
- Mixed germ
cell tumors
- Tumors of the
Meninges
- Meningioma
- variants:
meningothelial, fibrous (fibroblastic), transitional (mixed),
psammomatous, angiomatous, microcystic, secretory, clear
cell, chordoid, lymphoplasmacyte-rich, and metaplastic
subtypes
- Atypical
meningioma
- Anaplastic
(malignant) meningioma
- Non-menigothelial
tumors of the meninges
- Benign Mesenchymal
- osteocartilaginous
tumors
- lipoma
- fibrous
histiocytoma
- others
- Malignant
Mesenchymal
- chondrosarcoma
- hemangiopericytoma
- rhabdomyosarcoma
- meningeal
sarcomatosis
- others
- Primary
Melanocytic Lesions
- diffuse
melanosis
- melanocytoma
- maliganant
melanoma
- variant
meningeal melanomatosis
- Hemopoietic
Neoplasms
- malignant
lymphoma
- plasmactoma
- granulocytic
sarcoma
- Tumors of
Uncertain Histogenesis
- hemangioblastoma
(capillary hemangioblastoma)
- Tumors of Cranial
and Spinal Nerves
- Schwannoma
(neurinoma, neurilemoma)
- cellular,
plexiform, and melanotic subtypes
- Neurofibroma
- circumscribed
(solitary) neurofibroma
- plexiform
neurofibroma
- Malignant
peripheral nerve sheath tumor (Malignant schwannoma)
- epithelioid
- divergent
mesenchymal or epithelial differentiation
- melanotic
- Local Extensions
from Regional Tumors
- Paraganglioma
(chemodectoma)
- Chordoma
- Chodroma
- Chondrosarcoma
- Carcinoma
- Metastatic tumours
- Unclassified
Tumors
- Cysts and Tumor-like
Lesions
- Rathke cleft
cyst
- Epidermoid
- Dermoid
- Colloid
cyst of the third ventricle
- Enterogenous
cyst
- Neuroglial
cyst
- Granular
cell tumor (choristoma, pituicytoma)
- hypothalamic
neuronal hamartoma
- nasal glial
herterotopia
- plasma cell
granuloma
A number of grading
systems are in common use for tumors of astrocytic lineage (i.e.
astrocytomas, anaplastic astrocytomas and glioblastomas). Grades
are assigned solely based on the microsopic appearance of the tumor.
The numerical grade assigned for a given tumor, however, can vary
depending on which grading system is used as illustrated by the
following table. Thus, it is important to specify the grading system
referred to when a grade is specified. The St. Anne/Mayo grade has
proven to correlate better with survival than the previously common
Kernohan grading system. It can only be applied to invasive tumors
of astrocytic lineage; it is otherwise similar to the WHO grading
system.
Grading
of astrocytic tumors
WHO designation WHO grade* Kernohan grade* St. Anne/Mayo grade St. Anne/Mayo criteria
pilocytic astrocytoma I I excluded -
astrocytoma II I, II 1 no criteria fulfilled
2 one criterion: usually
nuclear atypia
anaplastic III II, III 3 two criteria: usually
(malignant)astrocytoma nuclear atypia and mitosis
glioblastoma IV III, IV 4 three or four criteria:
usually the and/or necrosis
*The WHO and Kernohan
systems are not criteria based. Thus, a given tumor may not fall
under the same designation in all three systems.
Mutations
leading to infiltrative astrocytic tumors.
Molecular studies
have identified some of the genetic changes that underlie the pathologic
differences among astrocytic tumors; progression in tumor grade
is associated with an ordered accumulation of mutations (Fig. below).
Approximately 33% of low grade infiltrating astrocytomas (St. Anne/Mayo
grade 2) have mutations detected in the p53 gene on chromosome 17p.
Anaplastic astrocytomas (grade 3)-whether found in preexistent low
grade astrocytomas or detected de novo-have a similar incidence
of p53 mutations but, in addition, show a loss of heterozygosity
on chromosome 19q in more than 40% of cases. Progression from astrocytoma
to anaplastic astrocytoma also involves mutations in other tumor
suppressor genes including the retinoblastoma gene on chromosome
13q. Finally, glioblastomas have the same incidence of these genetic
aberrations and in addition 70 percent have lost heterozygosity
for chromosome 10 and one third have amplification of the epidermal
growth factor receptor gene. Many of these correlations have been
defined largely through work in the MGH Molecular
Neurooncology laboratory.
Molecular genetic
alterations in infiltrative astrocytic tumors . The genetic
aberrations identified accumulate in a fixed percentage of tumors
at each stage of malignancy. The proportion of tumors with mutations
characteristic of less anaplastic tumors remains constant as anaplasticity
increases. Thus, astrocytic tumors vary with respect to the subset
of these mutations which are detected. Neoplastic cells are clonal.
Abbreviations: LOH = loss of heterozygosity, p = short arm of chromosome,
q = long arm of chromosome, Rb = retinoblastoma gene, EGFr = epidermal
growth factor receptor.
For
detailed information and references see:
- Tatter
SB , Wilson CB, Harsh GR IV.
Neuroepithelial tumors of the adult brain. In Youmans JR, ed.
Neurological Surgery, Fourth Edition, Vol. 4: Tumors. W.B.
Saunders Co., Philadelphia, pp. 2612-2684, 1995.
- Kleihues P,
Burger PC, Scheithauer BW. The new WHO classification of brain
tumours. Brain Pathology 3:255-68, 1993.
- Lopes MBS, VandenBerg
SR, Scheithauer BW. The World Health Organization classification
of nervous system tumors in experimental neuro-oncology. In A.J.
Levine and H.H. Schmidek, eds. Molecular Genetics of Nervous
System Tumors Wiley-Liss, New York, pp. 1-36, 1993.
To
the MGH Neurooncology Homepage for more
information on on-line neurooncology (brain tumor) resources.
|